DEFA14A: Reviva Pharma Corrects Reverse Split Share Data

Reviva Pharmaceuticals Holdings, Inc. issued a supplement to its definitive proxy statement, correcting previously understated figures related to its proposed reverse stock split.

Summary

• A supplement to the Definitive Proxy Statement dated November 4, 2025, was filed by Reviva Pharmaceuticals Holdings, Inc. (Reviva, the Company).
• The supplement corrects an inadvertent understatement in the 'Number of Shares of Common Stock Authorized but Unissued and Unreserved' line item within Proposal 5 (the Reverse Stock Split Proposal).
• The corrected table provides estimated post-Reverse Split figures for various ratios (1:2, 1:10, 1:20) and includes historical share data and stock price information as of October 21, 2025.
• The proposed reverse split will not affect proportionate voting rights or the number of stockholders of record, except for adjustments related to fractional shares.
• The company's authorized common stock remains 315,000,000 shares under its current Certificate of Incorporation.
• If the 'Increase in Authorized Proposal' passes, the authorized shares would increase to 515,000,000.
• The common stock is expected to continue trading on Nasdaq under the symbol RVPH, with a likely temporary 'D' suffix for 20 trading days post-split, assuming compliance with the Minimum Bid Price Requirement is regained.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the correction itself is positive for transparency and accuracy, the underlying reason for the reverse split (low stock price and Nasdaq compliance issues) is generally a neutral to negative signal. This supplement does not introduce new material information that would fundamentally alter the company's financial health or prospects, but rather clarifies previously disclosed details.

Positives

• The company has provided corrective disclosure, enhancing the accuracy and transparency of information available to stockholders regarding the proposed reverse stock split.

Negatives

• The initial proxy statement contained an inadvertent understatement of key share data, indicating a minor oversight in disclosure.
• The underlying need for a reverse stock split often signals a low stock price, which is generally a negative indicator of company performance and market perception.

Risks

• There is a risk of not regaining compliance with the Nasdaq Minimum Bid Price Requirement, which could lead to delisting.
• Adjustments may result from the treatment of fractional shares following the reverse stock split.

Future Outlook

The company anticipates that its common stock will continue to be reported on Nasdaq under the symbol RVPH, with a temporary 'D' suffix for twenty trading days after the effective date of the reverse split, assuming it successfully regains compliance with the Minimum Bid Price Requirement. The proposed reverse split is intended to increase the per-share price to meet these listing requirements.

Management Comments

• Reviva is providing this supplement to reflect updates to the disclosure in the Proxy Statement, specifically to correct inadvertently understated estimated post-Reverse Split figures.

Industry Context

Reverse stock splits are a common corporate action, particularly for smaller or development-stage companies, to increase their per-share stock price. This strategy is frequently employed to meet minimum bid price requirements of major stock exchanges like Nasdaq, thereby preventing potential delisting and maintaining investor confidence and liquidity.

Corporate Governance

Stakeholder Impact

• Shareholders: Will own a reduced number of shares post-split, but proportionate voting rights remain unaffected (except for fractional shares). The reverse split aims to increase the per-share price, potentially helping the company maintain its Nasdaq listing. The 'Increase in Authorized Proposal' could lead to future dilution if new shares are issued.

Next Steps

• Stockholders will vote on the Reverse Stock Split Proposal and the Increase in Authorized Proposal at the Annual Meeting scheduled for December 18, 2025.
• If approved, the Reverse Split will become effective, and the company will work towards regaining compliance with Nasdaq's Minimum Bid Price Requirement.

Key Dates

Keywords

Reviva Pharmaceuticals, RVPH, SEC filing, DEFA14A, Proxy Statement, Reverse Stock Split, Share Capital, Nasdaq Compliance, Stockholders Meeting, Corporate Governance